CFN Insider

CFN Insider #6: The US Cannabis Market: New Promise, Persistent Constraints

July 19, 2018 Season 1 Episode 5
CFN Insider
CFN Insider #6: The US Cannabis Market: New Promise, Persistent Constraints
Chapters
CFN Insider
CFN Insider #6: The US Cannabis Market: New Promise, Persistent Constraints
Jul 19, 2018 Season 1 Episode 5
CFN Media
FDA Approvals, DEA Rescheduling, and Much More
Show Notes

CFN Insider explores how the U.S. cannabis industry is evolving and the potential impact of a DEA decision to reschedule the drug or its cannabinoid constituents with a leading market analyst and group of five legal experts. In addition, investment opportunities are identified that may arise from these changes.

In this episode, we take a look at some of the latest developments:

  • FDA Approves GW Pharma's Epidolex
  • Impact on rescheduling cannabis and DEA's rescheduling possibilities (isolate vs. cannabis plant)
  • Resulting investment plays (cannabinoid drug developers, hemp extracts)
  • Legalization Roundtable: State cannabis programs are flourishing (on both coasts) and fairing well under the Trump Administration on a macro level in light of the Cole Memo rescission, but federal restraints persist

Guests on the podcast include:

  • Matt Karnes, Greenwave Advisors
  • Rod Kight, Kight Law
  • Seth Goldberg, Duane Morris LLP
  • Silvia San Nichols, CEO of New Game Compliance
  • Justin Hobson, Lane Powell
×

Listen to this podcast on